Eyegate Pharmaceuticals (NASDAQ: EYEG) and Teligent (NASDAQ:TLGT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Eyegate Pharmaceuticals and Teligent, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyegate Pharmaceuticals 0 0 4 0 3.00
Teligent 0 1 2 0 2.67

Given Eyegate Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eyegate Pharmaceuticals is more favorable than Teligent.

Earnings & Valuation

This table compares Eyegate Pharmaceuticals and Teligent’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Eyegate Pharmaceuticals $670,000.00 29.29 -$13.34 million ($1.30) -0.88
Teligent $66.88 million 4.13 -$11.98 million ($0.16) -32.31

Teligent has higher revenue and earnings than Eyegate Pharmaceuticals. Teligent is trading at a lower price-to-earnings ratio than Eyegate Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Eyegate Pharmaceuticals has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500. Comparatively, Teligent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Insider and Institutional Ownership

13.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.6% of Teligent shares are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Teligent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Eyegate Pharmaceuticals and Teligent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%
Teligent -11.36% 1.49% 0.46%


Teligent beats Eyegate Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

About Teligent

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.